Featured Articles, Medical

Hair Cloning Is Coming

Hair Cloning Is Coming

HairClone is a unique International partnership of Scientists, Hair Transplant Surgeons and Patients created to develop treatments for hair loss.

The most common type of hair loss in men and women (androgenetic alopecia) is caused by the affected hair follicles losing their natural regenerative abilities, causing them to miniaturize, producing the appearance of thinning hair.

HairClone is developing a treatment to replace these lost cells. A few of a patient’s non-affected follicles will be harvested in a simple out-patient procedure. Potent cells will be isolated from these follicles, multiplied in the laboratory, and micro-injected into the affected part of the scalp with the intention of rejuvenating the hair shafts, making them thicker and longer.

To learn more about this 2nd generation cell multiplication project, The Hair Authority met with HairClone’s CEO, Dr. Paul Kemp and Medical Director, Dr. Bessam Farjo.

Kemp,
PhD
Chris Webb,
Editor, NHA
Paul Bessam Farzo
MB, CHB, BAO, LRCP & SI

 

Authority:  Dr Farjo, we have known each other for over 15 years, and we’ve seen many technologies come and go. One of these was cell multiplication, but now it’s back. What has changed?

Dr. Farjo:  Two things. Our increased understanding about hair loss and the fact that we now have more practical expectations. As you point out, we have been down this road before under another venture which was called Intercytex. The idea of culturing hair cells, multiplying them in the lab and injecting them to make new hair has been the goal of scientists for a long time. Ever since people succeeded in growing cells in a lab, researchers have tried and failed to produce cosmetically significant new hair growth. We tried here in the UK, and other people tried in the in the USA, but without success.

However, as I mentioned, a number of things have changed since then. Technology has evolved, notably the ability to ”interrogate” and determine all the proteins that they are making and examine how this changes when the cells are cloned. We can use this to better develop the culture systems as we’ve learned that these cells have what you might call a “program” attached to them, and you need to maintain that ‘programming’ for them to produce the correct signals for hair rejuvenation. Previous technologies did not protect that “programming” and prevent it from dissipating, so the cells forgot what they were supposed to do and what they were supposed to produce.

The other thing is that is fundamentally different is what we are trying to achieve. At the beginning, everybody felt very heroic and thought, “We’ll produce these cells, put them in a bald head and voila new mature hair will grow!”  But over the decades, science has shown that new hair growth is much more complicated than that. It’s multifactorial and there’s a lot we still don’t know. However, there has  been a lot more research and as a result, hair growth out of culture has become more predictable. One key discovery is that we’ve learned we can rejuvenate thicken existing miniaturizing hair.

In the past, we noticed that some areas of thinning hair had thickened up, but that didn’t seem very exciting because everybody wanted to grow new hair from nothing.  However, attitudes have changed and today there’s a lot more emphasis on preservation rather than waiting for everything to fall apart and then trying to recreate it.  As a result, there’s a growing market for thickening existing hair and preventing hair from getting to that advanced thinning stage in the first place.

So, to summarize, the two principles that have changed are firstly the technology that makes these cells grow better quality hair, and secondly, the fact that we’ are now aiming to prevent hair loss rather than reverse end-stage baldness. We believe rejuvenating existing hair is a more attainable goal than creating hair from scratch. Also, this repair of existing hairs will maintain their natural distribution and direction of growth.

 

Authority:  It has always been hard to define our business. Is it “hair rejuvenation,” “hair restoration,” “hair replacement,” or “hair preservation?” At the Hair Authority we use the term, “Hair Management” which covers all bases.  And while we are talking terminology, hair consultants we’re always instructed not to talk about “hair cloning” and use medical language like “follicular neogenesis” instead.  However, your new company is actually called “HairClone.” What has changed?

Paul Kemp:  To understand how this came about we really need to wind back the clock. I started in regenerative medicine in Boston with a company called Organogenesis. We were trying to build skin, but it quickly became obvious that this would be really expensive since we first had to build tissue in a dish and then there were limitations as to what we could do with it.  So, when I returned to the UK and set up Intercytex, we took a different approach. This time, we tried to build the tissues actually in the patient rather than in a dish and then transplanting it.

This was about the time that Colin Jahoda was publishing his work on using dermal papilla cells and generating hair follicles, a process he called, “follicular neogenesis.” When we looked at what he was doing with follicles, hair appeared to be a more promising target than skin. It seemed simple; implant or inject cells into the skin and a new hair formed.  So, we thought, Bingo, we could create these new hairs, just by using cell suspensions!  So, that’s how we started our hair work at Intercytex and how I got to know Dr. Farjo.  We moved quickly and embarked on our first clinical trials. The goal was to demonstrate that we could create brand new hair follicles.

 

Authority: You assembled a powerful research team with impressive credentials. How did you all come together?

Paul Kemp:  We set up Intercytex, as a classic startup biotechnology company. The typical game plan is you raise a lot of money from venture capital, then float on the stock market. Then you raise another ton of money, and you get products to the clinic. And then Big Pharma buys you. That’s generally the process and Intercytex raised just short of 60 million pounds sterling.  But the problem with doing that is you’re then on this treadmill or escalator and you can’t stop. It’s not your escalator; you’re driven by the investors’ timelines and you have to keep generating more income. I spent most of my time raising money when what we really needed to do was focus on the goal of multiplying and implanting hair cells.  Someone once used a great analogy. He said, “You just have to run at the brick wall. And the faster you run at the brick wall, the greater the likelihood you might burst through it or just splat against the wall.” That’s the problem; you only get one shot at it.  We didn’t create new hairs, although there were some fine hairs that weren’t  cosmetically useful.  We were making progress, but it wasn’t enough. You can’t go back to the venture capitalists and say, “Can we have another 50 million please” and try again.

 

Authority: If you were pitching a venture capitalist today and you had one minute to him excited, how would you summarize your new goals?

Paul Kemp:  Rebuilding miniaturizing hairs.

 

Authority:  If  the new HairClone program goes according to plan, who could participate? Is there an age limit, gender limit or hair loss qualification?

Dr. Farjo:From all that we know now and all we’ve gained from the Intercytex and Aderans Research Institute days… and from things that Replicel and Shiseido have done… the prime targets are people with Norwood two/three, maybe four. Men and women are both fine, but with early stages of hair loss. What everyone seems to have shown is that miniaturizing hairs can be rebuilt, but only to a certain point. Hairs  can go beyond a point of no return and get too small to be rebuilt. So, for someone who is category six or seven, you may be able to repair and rebuild some of their hair at the margins, but those hairs in the central area have probably miniaturized too far. You need to catch them early on just before the point where it becomes impossible to rejuvenate them.

We’re targeting early stage hair loss. Women are great examples because they tend to thin rather than go bald. They have plenty of hair that you could work with. Men can be more challenging.

In most of the experiments people have done in the past, they showed somebody with a with a bald patch in the center and a zone around that bald patch where was is some vague thinning. They injected the bald patch with cells and found that nothing happened in the bald patch – but in the surrounding area, things started to look better. Nobody paid attention to that surrounding area however, because it wasn’t the original target. They missed the important fact that you can apparently rebuild existing hair in the thinning area, even if you could not repopulate a bald spot. So, our goal is to catch those people who have that thinning zone. If they already have a bald patch, they may be candidates for a hair transplant, but if we can catch them before they develop a bald patch then there’s hair that we could bring back to life.

 

Authority:  Could you envisage a time where people have an annual “hair physical?”  Your doctor checks your vital signs, examines your scalp and tells you to bank some hair cells because your hair is vibrant today, but it would be prudent to plan for the future.

Dr. Farjo:  Makes sense. People are already scheduling regular dental checkups and watching their cholesterol, so it’s logical to expect them to ask what else needs to be protected?

 

Authority:  Are you considering expanding into other areas of personal care?

Paul Kemp:  One of the things that attracts venture capitalists is biotech companies with a strong product pipeline; a whole series of products in development. RepliCel is a  good example of a company that is exploring multiple technologies and medical targets. They’re doing tendons as well as hair. We wanted to just work on hair, and you might say we nailed our colors to the mast with our company name. HairClone is an accurate description of our work, which is cloning hair cells.  Another reason to call ourselves HairClone was so we stayed focused on to rebuild miniaturizing follicles and couldn’t go off and work on some other area and dilute our efforts in hair.

 

Authority:  There is an Italian company that is promoting the implantation of synthetic fibers into the scalp. This has been banned in many countries. Have there been advances in artificial hair fibers that now make this a safe procedure?

Dr. Farjo:  Synthetic materials like this have been around for a long time.  Although people claim they’ve improved their technology and their fibers don’t cause as much inflammation, it’s still an unproven field. I think there’s an Israeli company that about two years ago was claiming that their material was completely inert and didn’t cause any reaction, but the point remains that it’s a still a foreign body and if you have the option, it’s always better to restore living hair. I don’t want to dismiss artificial hair completely, but we don’t practice this because of the risk of infections and tissue necrosis.

 

Authority:  Returning to hair cloning, can a patient “double dip?”  In other words, can she have one initial implant of her cloned hair cells, and then and have a second or third procedure later if she still has reserves in the bank

Dr. Farjo:  Yes, that’s exactly the plan.  When we bank follicles, we don’t cryo-preserve them all in one tube.  We keep them in multiple tubes so we can thaw them out one tube at a time, isolate the cells we need from those few follicles, clone them and use them for one specific treatment.

Paul Kemp:  The idea is that we can support the patient over time as his or her hair loss progresses. Patients may have hair follicles that have miniaturized beyond the point of recovery, but there will also be follicles that are destined to miniaturize but haven’t done so yet. Those follicles haven’t started miniaturizing yet, and we obviously can’t treat them today, but we can be ready when they do. So, the idea is to be ready to help patients as this wave of miniaturization progresses.

 

Authority:  A few practical questions: When a patient comes in for a consultation, how do you determine if they qualify?  What is involved in the actual procedure? Does it hurt?  How long does it take?  Where do those cells go? What happens next?

Dr. Farjo:  Since the end of 2019, when we first received a license to bank cells, I’ve been offering hair banking as an option to my patients. I present it in the same way that I discuss the benefits of finasteride, Minoxidil, PRP, lasers and hair transplants. I explain that banking their cells for the future could become a way to rejuvenate their hair when new technology becomes available.  If they say, “Okay, I want it done,” I’ll explain that it involves a minor procedure that’s like half a regular hair transplant.  I will just need to remove 100 hair follicles by FFP and that’s it. To treat 100 hair follicles, I need about 40 to 50 grafts. It’s all done under local anesthetic.  We remove the grafts, insert them into special tubes and place them in a tissue freezer.  We can do this without shaving the patient’s head and it’s all over and done with in under half an hour.

That’s the end of the matter as far as the patient is concerned, but when the treatment becomes available, we will withdraw somewhere between five and ten follicles that we will use to dissect out the basic cells, the progenitor cells, which then get grown into a culture.  A few weeks later, the new cells will be ready. The patient gets called back and it’s a little bit like a PRP session.  You anaesthetize the area at the top and you give individual injections of the cells that are ready and held in solution.  It may take half an hour or so to inject these cells.

 

Authority:  How long can you preserve these hair follicles?

Dr. Farjo:  We use a specialized tissue freezer that chills the tissue at a very slow speed to preserve the viability of the tissue and stop ice from forming in the in the follicles themselves.  Once it’s frozen, it’s cryo-preserved and goes into long term storage in a tissue bank.  The one we’re using is in Sheffield in Yorkshire, UK. We don’t yet have long term data with follicles, but we know many different types of tissue can be safely preserved for at least 20 years.

We anticipate that people may need treatments once every hair cycle. So, if the adult hair cycle is a couple of years, we anticipate that initially, they might need a new treatment] every two years. However, this is not something they have to do forever.  After two or three sessions, some patients may not need any more treatments, so compared to other rejuvenation therapies, it could result in a permanent solution.

Paul Kemp:  The thing that has changed from the early Intercytex days to these HairClone days is an incredible increase in our basic understanding of hair follicle biology.  This gives us abilities that we couldn’t dream of in the Intercytex days.  Now we can now look at the complete genetic profile of an individual cell in a single hair.  It’s called *transcriptomics. Every cell in the body has the same genetic profile, but there are certain genes that get turned on and turned off in different cells. The transcriptome is the gene that is turned on. We now know that hairs from this region come from a different developmental origin compared to other hairs. When the fetus is developing and your face is forming, these dermal papilla cells retain a positional memory. That’s why you can transplant them. They remember their transcriptomic profile when you transplant them.  So, we plan to take the dermal papilla cells from this region knowing from transcriptomic studies that they will maintain that memory, even in culture.  We will then expand them in culture and inject them into the affected region. To make things better, we also know from academic labs that dermal papilla cells can home in on the hair follicle, so you don’t need to actually inject them back into the follicle itself. They’ll hopefully move through the dermis into the dermal papilla region, migrate into the roots of the thinning hairs and repopulate them with cells that came from the donor area.

So, what you’re doing now is taking the controlling dermal papilla cells from the occipital region and having them populate hair follicles in the frontal region. What we haven’t shown yet, but hope to demonstrate, is that you will not only be able to rebuild these hairs, you can also change the character of frontal hairs and turn them into occipital hairs. If we’re right on this, then then that will be a permanent switch and they won’t continue to miniaturize.

 

Authority:  You said, “if we’re right.”  Where does the research stand at the moment?

Paul Kemp:  We’re on a fast track. We’ve decided to work with humans rather than start with animal studies because apart from the ethics of animal work, they can be an expensive distraction and so many studies have shown that animal hairs behave differently to human hairs.  We know we can expand these human cells in culture but what we can’t do yet from a regulatory point of view, is inject them back into someone’s head. In order to do that, we have to manufacture the cells following a GMP (good manufacturing practice) protocol, just as though we were going to do an actual clinical trial. We are doing this in collaboration with Newcastle University using an “Innovate UK” government grant, but Covid-19 came along which has delayed things.  We’re continuing to work on the GMP system which requires a lot of paperwork, a lot of quality control and so on. Once we’ve completed this, the regulations in the UK will allow Dr Farjo’s clinic to prescribe those cells and implant them back into the patient. And then exciting part begins as look and see if we’re right about converting those frontal hairs and rebuilding them.

 

Authority:  Why is the research being conducted in the UK?

Dr. Farjo:  Primarily because of the regulations. In order to conduct a clinical trial, you have to get permission from the regulatory body, which is the FDA in America.  In the UK, it’s the MHRA (Medicines and Healthcare products Regulatory Agency).  The first stage is called a CTA or “Clinical Trial Application” where you are required to define three things;  “What is the product I’m going to use?”, “What type of patient am I going to treat?” and finally, “What am I going to do to those patients?” Those three things together become the CTA, and you’re then stuck with that protocol. You just have to hope that you are right, that you picked the right patients, product and procedure. It’s not easy, I know from experience. I’ve probably done 30 trials with cell therapies and it’s always an educated guess. That’s where the UK provision give you some flexibility. There is a provision in the UK regulations called “Specials.” As long as you accurately define what you’re going to use, and you manufacture it to the same quality that you would use in a clinical trial in a facility like that in Newcastle which is licensed by the MHRA to produce cell based “Specials”, then the other two criteria are left up to the clinician who is working in the special medical interest of the patient. The clinician can pick who they feel is the most appropriate patient population and they can apply the GMP manufactured product in the manner they judge best using their professional skills.

Technically, this is not a “clinical trial,” but does allow us to try different iterations. Once we have an iteration that works, we can use that information to go head and design a classic clinical trial and run that study in the UK, US or Canada simultaneously to satisfy all the relevant authorities. The only catch with our initial UK study is since it is not a clinical trial, you cannot go to market. it’s just between the doctor and his patients.  You cannot promote any product or procedure or allow other doctors to do it. For that you need a marketing license, and for that you need the clinical trial.

 

Authority:  Can other professionals participate in your front-end research?

Paul Kemp:  This is part of a different business plan and funding structure. Let’s assume we now have this procedure and it works.  We can take a hundred hair follicles, bank them, grow them as the patient needs them and put them back.  It’s a personalized treatment with the same cells going back into the same patient. Our top concern now is quality control and safety. We want our new procedure of hair cloning to have the highest level of security.  We need to be sure that the clinician who’s taking the hair follicles out and putting them back is doing it appropriately. We don’t just want to create some cells that we ship off and not know what people will do with them. So, we plan to take the ethical quality hair transplant surgeons and work with them to develop this system together. In return, we’re giving them regional exclusivity.

 

Authority:  Could you take follicles from one individual and neutralize them so they would be accepted by a different recipient?

Paul Kemp:  I don’t think so. Possibly a long time in the future. We don’t yet understand the immunology of using cells genetically.  For example, we know alopecia areata is an autoimmune problem so we wouldn’t want to be in a scenario where we’re stimulating something like that?  On a practical level, in order to do that, you would have to do a huge amount of viral safety testing. And in order to make that cost effective, you’d have to create huge banks of cells which would require a large amount of starting material.

 

Authority:   With earlier hair multiplication studies there was a problem with “angularity,” the angle at which hair  emerged from the scalp. It was hard to create a satisfactory cosmetic solution. Is that still an issue?

Dr. Farjo:  No, because we’re rebuilding, or revitalizing the patient’s existing hair follicles. We’re simply enhancing an existing structure.

 

Authority:  With a regular hair replacement or hair system, you get more hair immediately. With a hair transplant, you will see results in a few months.  But you are asking patients to invest in something that is not yet available. What is their response?

Dr. Farjo:  Obviously, one of the things people say is , “Well, you haven’t got the treatment yet. Why should I bank my hairs now? I’ll wait till you come up with something that works.”  That’s a common question in my consultations and there are several answers. One thing we didn’t mention earlier is that hair goes through other changes in addition to genetic alopecia. It goes through an aging process, just like every other cell in the body.  We’ve proven in university studies that hair from a man in his 50’s or 60’s is different from hair from somebody in their 20’s and 30’s. The way the way they respond to stem cell proliferation and culturing is very different.  The younger hair cells are more vital and resilient. In fact, when we’re working with researchers, they always ask us to send them young patients’ hair because it will maintain its characteristics after cryo-preserving and if you use those hairs in years to come, you can expect to get the same qualities of the younger hair.

We tell patients that rather than waiting until you’ve lost your hair and then try to revitalize it with old, fatigued hair, it’s better to bank your quality hair today. Stopping the aging clock is the first reason to bank as soon as possible. The second takes us back to our business plan. All the funds we raise from banking are put back into research. Follicle banking allows us to generate funds without resorting to outside investors – and we like the fact that our patients become part of the process too.

 

“Transcriptome” – A transcriptome is the full range of messenger RNA, or mRNA, molecules expressed by an organism. The term “transcriptome” can also be used to describe the array of mRNA transcripts produced in a particular cell or tissue type. In contrast with the genome, which is characterized by its stability, the transcriptome actively changes. In fact, an organism’s transcriptome varies depending on many factors, including stage of development and environmental conditions.

5 thoughts on “Hair Cloning Is Coming”

  1. Angela Markens says:

    it is a good research

  2. Mike Ethans says:

    True. Prevention is better than cure.

  3. Sealey Thomas says:

    Good invention done by Mr.Paul Kemp it will be helpful for people who have interested to re-plantation of their hairs.

  4. Simon Mathews says:

    Great work

  5. Simon Mathews says:

    Impressive.